(A) Agilent Technologies, Inc. Company Overview

What does Agilent Technologies do?

Agilent Technologies, Inc. is a laboratory technology company serving life sciences, diagnostics, and applied markets. In plain English, Agilent sells the instruments, software, consumables, reagents, services, and specialty manufacturing capabilities that laboratories use to identify, quantify, and analyze samples. Its customers include pharmaceutical and biotechnology companies, clinical labs, academic and government researchers, food-safety labs, environmental and forensic labs, and chemicals or advanced-materials customers.

The current company is not a general electronics measurement business anymore. Agilent was incorporated in Delaware in May 1999 and now describes itself in its FY2025 Form 10-K as a global leader in life sciences, diagnostics, and applied markets, with application-focused solutions for the full laboratory workflow. That workflow orientation matters because it makes Agilent more than an instrument vendor: an installed instrument can pull along methods, columns, consumables, software, service contracts, automation, compliance work, and future replacement demand.

How is the business organized?

Agilent reorganized its reporting structure in fiscal 2025 into three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The first segment includes liquid chromatography, liquid chromatography mass spectrometry, cell analysis, pathology, genomics, biomolecular analysis, and specialty contract development and manufacturing for oligonucleotide-based therapies. CrossLab spans services, consumables, software, automation, and lab-productivity solutions. Applied Markets includes gas chromatography, spectroscopy, vacuum, and remarketed instruments used in food, environmental, chemicals, energy, semiconductor, battery, and forensic applications.

Why does Agilent matter in laboratory workflows?

Agilent matters because laboratories tend to value reliable workflows, validated methods, service support, and application know-how as much as hardware. The company’s investor overview says most of the world’s labs use Agilent solutions and lists roughly 285,000 labs using its products or services, while Agilent’s January 2026 healthcare conference presentation points to 110 countries served and a broad installed base. For students and investors, that means the company should be studied as an installed-base, consumables, service, and replacement-cycle business, not only as a cyclical equipment seller.

How does Agilent make money across instruments, consumables, services, and CDMO work?

Agilent’s revenue model combines one-time product sales with recurring or repeatable lab-spend categories. Instruments are important because they place Agilent’s technology into a customer’s workflow. Non-instrumentation revenue is strategically important because it includes contract and per-incident services, companion diagnostics, CDMO work, spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses, and related services. In FY2025, products generated $4.94B, or 71% of total revenue, while services and other revenue generated $2.00B, or 29%.

Which revenue streams are most resilient?

The mix is shifting toward services, consumables, software, and other repeatable categories. Agilent’s January 2026 investor presentation says services, consumables, and software rose from 58% of revenue in FY2020 to 65% in FY2025. That movement improves the quality of the revenue base because installed instruments can create recurring demand for consumables, service, compliance, software, and automation. It does not remove cyclicality: instrument replacement cycles and customer capital budgets still matter, especially in pharmaceutical, chemical, and applied markets.

Which end markets pay Agilent?

The end-market mix is intentionally diversified. In FY2025, pharmaceutical and biopharmaceutical customers were the largest end market at $2.51B, followed by chemicals and advanced materials at $1.56B, diagnostics and clinical at $1.03B, environmental and forensics at $674M, food at $637M, and academia and government at $540M. This diversified exposure makes Agilent less dependent on a single customer group, and the FY2025 10-K states that no customer represented 10% or more of total revenue in 2025, 2024, or 2023.

Which segments matter most to revenue and profit?

Agilent’s segment story is not just about which unit is largest by sales. CrossLab is the highest-margin segment, Life Sciences and Diagnostics Markets carries much of the biopharma, diagnostics, pathology, genomics, and specialty CDMO strategy, and Applied Markets brings exposure to testing needs in chemicals, food, environment, energy, semiconductors, batteries, and forensics.

Why is CrossLab the profit engine?

CrossLab combines service, consumables, software, lab automation, and enterprise productivity solutions. In FY2025 it produced 42% of revenue but 53% of reportable segment income, making it the clearest margin anchor in the portfolio. A student building a business model canvas would treat CrossLab as both a revenue stream and a customer-retention mechanism: the segment monetizes the operational life of the lab, not only the original instrument sale.

How do segment economics compare?

What did Agilent's latest quarter show?

The freshest official reporting period is the second quarter of fiscal 2026, ended April 30, 2026. Agilent reported Q2 FY2026 revenue of $1.83B, up 10.0% reported and 6.3% core year over year. GAAP net income was $339M, diluted EPS was $1.20, and non-GAAP EPS was $1.49. The quarter is important because growth was broad across all three segments and the company raised full-year FY2026 guidance.

Which segment grew fastest in Q2 FY2026?

Applied Markets grew fastest on a reported basis, with Q2 FY2026 revenue of $344M, up 14% reported and 11% core. Life Sciences and Diagnostics Markets generated $732M, up 12% reported and 9% core. CrossLab remained the largest quarterly revenue contributor at $759M, up 6% reported and 2% core, and reported the highest operating margin at 32.0%. That mix tells a nuanced story: the fastest growth came from instruments and applied markets, while the highest margin still came from service-led CrossLab.

What does the latest end-market mix show?

For a DCF model, the latest quarter changes the near-term revenue base and margin setup more than it changes the long-term thesis. The key question is whether Q2 FY2026 reflects a durable replacement-cycle recovery and operating leverage from the Ignite Operating System, or only a strong comparison against a weaker prior-year period.

What strategic turning points still shape Agilent today?

Agilent’s history is best understood as a narrowing and deepening of focus. The company began with Hewlett-Packard measurement roots, but the current investment case is about lab workflows, life-science tools, diagnostics, services, and applied testing. The most important historical events are the ones that changed the portfolio, the margin structure, or the customer base.

1. 1999
   Agilent was formed from Hewlett-Packard’s test-and-measurement and related businesses, creating an independent measurement company with inherited engineering credibility and a public listing.
2. 2012
   The acquisition of Dako expanded Agilent’s diagnostics and pathology position, helping make clinical and cancer-diagnostics workflows a larger strategic focus.
3. 2014
   Agilent completed the spinoff of Keysight Technologies, separating electronic measurement from the life-sciences, diagnostics, and applied-markets company that kept the Agilent name.
4. 2024
   Agilent acquired BIOVECTRA, adding specialty CDMO capabilities for complex therapeutic modalities; the FY2025 10-K says BIOVECTRA contributed about 2 percentage points to FY2025 revenue growth.
5. 2025
   The company recast itself into three segments, aligning reporting around Life Sciences and Diagnostics Markets, CrossLab, and Applied Markets.
6. 2026
   Agilent completed the Biocare Medical acquisition, a pathology expansion expected by management to improve top-line growth, margin profile, and non-instrument revenue mix in its first year.

Why does the 2014 split matter today?

The Keysight separation is the defining strategic simplification. It made Agilent easier to analyze as a life-science and laboratory workflow company, rather than a mixed electronics and healthcare measurement business. That matters for valuation because the relevant comparisons, risk factors, and capital-allocation priorities became more focused on laboratory instrumentation, consumables, diagnostics, service, and regulated customer workflows.

Why do BIOVECTRA and Biocare matter?

BIOVECTRA and Biocare both deepen Agilent in areas where customers value technical specialization and repeat work. BIOVECTRA expands specialty CDMO capabilities across nucleic acid and advanced modalities. Biocare expands pathology antibodies, reagents, and instrument capabilities. Both moves show Agilent using M&A to increase exposure to non-instrumentation and clinically relevant workflows rather than merely adding broad lab-equipment scale.

What gives Agilent a competitive advantage in laboratory markets?

Agilent’s competitive advantage is not a single patent or brand slogan. It comes from workflow breadth, installed-base reach, application expertise, service coverage, regulatory familiarity, and the switching costs embedded in validated laboratory methods. Its FY2025 10-K identifies intense competition from companies such as Danaher-related businesses, Bruker, Roche Ventana, Shimadzu, Thermo Fisher Scientific, Twist Bioscience, Waters, PerkinElmer, and niche service providers, so the moat must be earned through execution rather than assumed.

Where is the moat strongest?

How does culture connect to strategy?

Agilent’s stated mission and values matter only insofar as they explain the model. The company says its mission is to deliver trusted answers and insights that advance quality of life, and its company information page emphasizes focus, accountability, integrity, teamwork, respect, and innovation. In this business, those are not soft claims alone: they map to customer trust, regulated workflows, product reliability, and the need to keep innovating as lab standards and scientific methods change.

What do competitors pressure?

Competition pressures pricing, product cycles, support quality, and innovation timing. Agilent competes on performance, reliability, applications expertise, support quality, whole-solution offering, global channel coverage, and price. The practical implication is that R&D, service execution, and product refresh cycles are not optional overhead; they are the cost of maintaining relevance in markets where Thermo Fisher, Danaher, Waters, Shimadzu, Bruker, Roche, and others can attack specific workflows.

How financially strong is Agilent?

Agilent is profitable, cash generative, and moderately leveraged, but its financial health should be evaluated through margins, free cash flow conversion, customer capital-spending cycles, and capital allocation. In FY2025, Agilent generated $6.95B of revenue, $1.48B of GAAP operating income, and $1.30B of net income. In the six months ended April 30, 2026, it generated $545M of operating cash flow and spent $169M on property, plant, and equipment, implying approximately $376M of free cash flow before acquisitions and financing uses.

What do cash flow and the balance sheet show?

How does capital allocation affect the story?

Agilent balances dividends, repurchases, capital expenditures, and acquisitions. In FY2025, it repurchased $425M of stock, paid $282M of dividends, and invested $407M in property, plant, and equipment. In the first half of FY2026, repurchases were $217M and dividends were $144M. The Biocare deal adds another capital-deployment signal: management is willing to use cash for targeted pathology expansion when it believes the asset improves growth, margins, and non-instrument revenue mix.

Who owns Agilent stock and how does governance matter?

Agilent is a one-share, one-vote public company with dispersed ownership and major passive institutional holders. That makes governance different from founder-controlled technology companies: management and the board must remain attentive to institutional investor expectations around capital allocation, board structure, executive pay, and long-term strategy. The company’s 2026 proxy statement lists 282,839,637 shares outstanding as of January 21, 2026 for ownership-percentage purposes.

Who are the largest disclosed holders?

What governance signals should researchers note?

The proxy states that Agilent separates the CEO and board chair roles, with Koh Boon Hwee serving as independent chair, and that all directors except CEO Padraig McDonnell meet independence standards. The board also recommended declassifying the board over a three-year transition, with all directors expected to be elected annually beginning at the 2029 annual meeting if approved. That proposal followed outreach to holders representing approximately 65% of the stockholder base after a 2025 stockholder proposal.

What opportunities and risks should researchers monitor?

Agilent’s opportunity set is tied to lab productivity, biopharma development, clinical pathology, chemical and materials testing, specialty CDMO capacity, instrument replacement cycles, and the company’s Ignite Operating System. Its risks are equally concrete: customer budget cycles, competition, product innovation timing, tariffs and trade controls, regulation, capacity mismatches, cybersecurity and privacy laws, and the challenge of integrating acquisitions without weakening execution.

Which risks are most company-specific?

What opportunities could change the story?

The most important opportunities are not abstract. A healthier instrument replacement cycle can raise product revenue and pull through future services. Specialty CDMO growth can deepen pharmaceutical exposure. Pathology expansion through Biocare can broaden clinical relevance. Digital ordering, service productivity, and automation can improve customer convenience and operating leverage. Agilent’s long-range model targets 5%-7% annual core growth and 50-100+ basis points of annual operating-margin expansion over a normalized 4%-6% market-growth backdrop, but those targets require sustained execution and are not guaranteed outcomes.

Which KPIs best explain Agilent's performance?

Agilent should be analyzed through both financial and operating KPIs. Revenue alone is not enough because the quality of revenue depends on mix, region, end market, service attachment, and whether growth is driven by recurring lab activity or discretionary instrument replacement. Margins alone are not enough because temporary restructuring, acquisition, and transformation costs can cloud core operating performance.

Which measures belong in a student or analyst dashboard?

Why does this matter for valuation?

In a DCF model, Agilent’s value is most sensitive to medium-term core growth, operating margin expansion, reinvestment needs, tax rate, working capital, and terminal margin durability. CrossLab can support more stable margins, while instrument replacement cycles and applied-market demand affect revenue volatility. M&A can add growth but also increases integration risk and cash deployment complexity.

What is the key takeaway from Agilent Technologies analysis?

Agilent is best understood as a focused laboratory workflow company with three linked engines: life-science and diagnostics innovation, CrossLab service and consumables economics, and applied-market analytical testing. The investment story is supported by a broad installed base, high-margin CrossLab economics, diversified end markets, a healthier FY2026 demand signal, and capital allocation that mixes reinvestment, dividends, repurchases, and targeted M&A.

What supports the company-specific thesis?

What should students, researchers, and investors monitor next?

The watchlist is concrete: Q3 and Q4 FY2026 core revenue growth, CrossLab margin stability, LDG growth after Biocare integration, Applied Markets replacement-cycle momentum, free cash flow conversion, China and Asia Pacific demand, debt and cash after acquisition spending, and whether the Ignite Operating System produces margin expansion without starving innovation. Agilent’s risk is not that it lacks a business model; the risk is that a strong installed-base model can still be pressured by customer capital budgets, product cycles, and intense global rivals.